SynAct Pharma AB reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was SEK 43.51 million compared to SEK 24.75 million a year ago. Basic loss per share from continuing operations was SEK 1.37 compared to SEK 0.91 a year ago. Diluted loss per share from continuing operations was SEK 1.37 compared to SEK 0.91 a year ago.
For the six months, net loss was SEK 93.39 million compared to SEK 44.81 million a year ago. Basic loss per share from continuing operations was SEK 2.96 compared to SEK 1.68 a year ago. Diluted loss per share from continuing operations was SEK 2.96 compared to SEK 1.68 a year ago.